Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.

Inanç M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R, Elmalı F.

Med Oncol. 2012 Dec;29(5):3119-24. doi: 10.1007/s12032-012-0250-8. Epub 2012 May 12.

PMID:
22580817
2.

D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.

Inanc M, Er O, Karaca H, Berk V, Ozkan M, Dikilitas M, Elmali F.

J BUON. 2013 Apr-Jun;18(2):391-7.

PMID:
23818351
3.

Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F.

Cytokine. 2002 Nov 24;20(4):184-90.

PMID:
12543084
4.

Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?

Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8.

5.

Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.

Inanc M, Duran AO, Karaca H, Berk V, Bozkurt O, Ozaslan E, Ozkan M.

Asian Pac J Cancer Prev. 2014;15(1):253-6.

6.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

PMID:
24370903
7.

Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.

Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, Kim HJ, Kwon HC, Lee JH.

BMC Cancer. 2010 May 14;10:203. doi: 10.1186/1471-2407-10-203.

8.

Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.

Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B.

Ann Oncol. 2002 Sep;13(9):1430-7.

PMID:
12196369
9.

Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis.

Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesini G.

Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S46-52. Epub 2011 May 13.

PMID:
21586218
10.

Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.

Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, Moore DF, Jabbour SK, Nosher JL.

J Vasc Interv Radiol. 2014 Feb;25(2):297-306.e1. doi: 10.1016/j.jvir.2013.10.030. Epub 2013 Dec 20.

11.

Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.

Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML; CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators.

Circulation. 2003 Feb 4;107(4):524-30.

12.

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M.

J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.

13.

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.

Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ, Xu RH.

J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. doi: 10.1007/s00432-009-0682-5. Epub 2009 Sep 24.

PMID:
19777259
14.

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.

Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J.

Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509.

PMID:
28621236
15.

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.

Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK.

Ann Oncol. 2002 Oct;13(10):1550-7.

PMID:
12377642
16.

Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.

Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N.

World J Gastroenterol. 2016 Jul 21;22(27):6287-95. doi: 10.3748/wjg.v22.i27.6287.

17.

Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.

El-Arab LR, Swellam M, El Mahdy MM.

J Egypt Natl Canc Inst. 2012 Mar;24(1):15-22. doi: 10.1016/j.jnci.2011.12.002. Epub 2012 Jan 17.

18.

Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.

Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, To KF, King AD, Ahuja A, Chan AT.

Cancer. 2013 Dec 1;119(23):4145-53. doi: 10.1002/cncr.28327. Epub 2013 Oct 1.

19.

Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.

Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M, Coskun U, Buyukberber S.

Asian Pac J Cancer Prev. 2012;13(3):1059-63.

20.

Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.

Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y.

Eur J Cancer. 1998 Dec;34(13):2041-5.

PMID:
10070308

Supplemental Content

Support Center